| Dr Kerry A Kaplan, OD | |
|
210 Maine Ave, Farmingdale, ME 04344-4515 | |
| (207) 582-5800 | |
| Not Available |
| Full Name | Dr Kerry A Kaplan |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 26 Years |
| Location | 210 Maine Ave, Farmingdale, Maine |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750458931 | NPI | - | NPPES |
| 122670000 | Medicaid | ME |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | OPT823 (Maine) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kennebec Eyecare Pa | 6406877703 | 4 |
News Archive
When doctors at a primary care clinic here noticed many of its poorest patients were failing to show up for appointments, they hoped giving out free rides would help.
MDCT arthrography is an accurate method for assessing cartilage loss in patients with hip dysplasia and may be more reliable than MRI in such instances, says a new study by researchers from Osaka University Medical School in Japan.
Pro-Pharmaceuticals, Inc., the leading developer of Galectin therapeutics to treat cancer and fibrosis, today announced it has entered into a new research collaboration with Mount Sinai School of Medicine to evaluate in pre-clinical models, the anti-fibrotic effects of several of the Company's novel, Galectin-targeting compounds.
The work of researchers Francesc Viñals and Mariona Graupera at the Bellvitge Biomedical Research Institute - Catalan Institute of Oncology - University of Barcelona, together with Dr. Antoni Riera-Mestre, has led to a new potential treatment for Hereditary Hemorrhagic Telangiectasia or Rendu-Osler Syndrome, a rare disease that affects blood vessels and had no described treatment.
› Verified 2 days ago
| Provider Name | Kennebec Eyecare Pa |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1659462067 PECOS PAC ID: 6406877703 Enrollment ID: O20051214000713 |
News Archive
When doctors at a primary care clinic here noticed many of its poorest patients were failing to show up for appointments, they hoped giving out free rides would help.
MDCT arthrography is an accurate method for assessing cartilage loss in patients with hip dysplasia and may be more reliable than MRI in such instances, says a new study by researchers from Osaka University Medical School in Japan.
Pro-Pharmaceuticals, Inc., the leading developer of Galectin therapeutics to treat cancer and fibrosis, today announced it has entered into a new research collaboration with Mount Sinai School of Medicine to evaluate in pre-clinical models, the anti-fibrotic effects of several of the Company's novel, Galectin-targeting compounds.
The work of researchers Francesc Viñals and Mariona Graupera at the Bellvitge Biomedical Research Institute - Catalan Institute of Oncology - University of Barcelona, together with Dr. Antoni Riera-Mestre, has led to a new potential treatment for Hereditary Hemorrhagic Telangiectasia or Rendu-Osler Syndrome, a rare disease that affects blood vessels and had no described treatment.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kerry A Kaplan, OD Po Box 1438, Waterville, ME 04903-1438 Ph: (207) 872-2797 | Dr Kerry A Kaplan, OD 210 Maine Ave, Farmingdale, ME 04344-4515 Ph: (207) 582-5800 |
News Archive
When doctors at a primary care clinic here noticed many of its poorest patients were failing to show up for appointments, they hoped giving out free rides would help.
MDCT arthrography is an accurate method for assessing cartilage loss in patients with hip dysplasia and may be more reliable than MRI in such instances, says a new study by researchers from Osaka University Medical School in Japan.
Pro-Pharmaceuticals, Inc., the leading developer of Galectin therapeutics to treat cancer and fibrosis, today announced it has entered into a new research collaboration with Mount Sinai School of Medicine to evaluate in pre-clinical models, the anti-fibrotic effects of several of the Company's novel, Galectin-targeting compounds.
The work of researchers Francesc Viñals and Mariona Graupera at the Bellvitge Biomedical Research Institute - Catalan Institute of Oncology - University of Barcelona, together with Dr. Antoni Riera-Mestre, has led to a new potential treatment for Hereditary Hemorrhagic Telangiectasia or Rendu-Osler Syndrome, a rare disease that affects blood vessels and had no described treatment.
› Verified 2 days ago
Smart Vision, Llc Optometrist Medicare: Medicare Enrolled Practice Location: 210 Maine Ave, Farmingdale, ME 04344 Phone: 207-582-5800 Fax: 207-588-0743 |